clinical trial · NCT07752121
First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms
Bristol-Myers Squibb·—·not yet recruiting·n = 190
Myelodysplastic NeoplasmsLuspatercept
brief summary
This study will observe adults with lower-risk myelodysplastic neoplasms (MDS) who have anemia requiring regular red blood cell transfusions and who are prescribed first-line luspatercept as part of routine medical care. The study will follow participants for up to 2 years to understand how often treatment leads to periods without transfusions, changes in hemoglobin levels, health-related quality of life, and safety outcomes. Information on treatment use and outcomes in routine clinical practice in Germany will also be collected.
started
Aug 24, 2026
primary completion
Aug 31, 2030
completion
Aug 31, 2030
last updated
Aug 7, 2026
official title
A Prospective, Multicenter, Non-Interventional Study Assessing First-line Luspatercept in Anemic Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Neoplasms Requiring Red Blood Cell Transfusions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol